2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Triple Negative Breast Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Cytarabine
561
Azacitidine
385
venetoclax
311
Cyclophosphamide
289
fludarabine
246
fludarabine phosphate
229
Decitabine
187
Busulfan
176
Daunorubicin
155
Idarubicin
151
Peripheral Blood Stem Cell Transplantation
138
Mycophenolic Acid
134
Filgrastim
134
Whole-Body Irradiation
133
Tacrolimus
125
Granulocyte Colony-Stimulating Factor
124
Etoposide
117
Mitoxantrone
103
Methotrexate
103
Melphalan
103
Cyclosporine
101
Antilymphocyte Serum
85
Gemtuzumab
84
Clofarabine
84
Specimen Handling
73
Injections
69
Stem Cell Transplantation
64
Biopsy
57
CPX-351
56
Thiotepa
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled